Skip to main content

Treatment Clinical Trials for Chronic Myelogenous Leukemia (CML)

Review the chronic myelogenous leukemia (cml) treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 44

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Status: Active
Location: 22 locations
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 15 locations
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Status: Active
Location: 8 locations
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Status: Active
Location: 7 locations
A Study of 131-I Apamistamab and CAR T-cell Therapy in Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Status: Active
Location: 7 locations
Orca Q Stem Cells for the Treatment of Pediatric Patients with Leukemia
Status: Active
Location: 4 locations
Inotuzumab Ozogamicin in Treating Patients with Acute Lymphocytic Leukemia after Transplant
Status: Active
Location: 4 locations
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 4 locations
ASCIMINIB, Dasatinib, Prednisone, and Blinatumomab in Treating Patients with BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, or Chronic Myeloid Leukemia
Status: Active
Location: 4 locations
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Status: Active
Location: 4 locations
Fludarabine and Intermediate-dose Total Body Irradiation Conditioning plus Post-Transplant Cyclophosphamide for the Treatment of Patients Undergoing Allogeneic Stem Cell Transplant for Hematologic Cancers
Status: Active
Location: 3 locations
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Status: Active
Location: 3 locations
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Olverembatinib for the Treatment of Chronic Myeloid Leukemia in Newly Diagnosed Patients in the Chronic Phase
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Asciminib for the Treatment of Patients with Chronic Phase Chronic Myeloid Leukemia
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Optimized Cord Blood Transplant with Intermediate Intensity Conditioning Regimen for the Treatment of Relapsed High-Risk Hematologic Cancers after First Donor Stem Cell Transplant
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients with High-Risk Hematologic Diseases
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients with Philadelphia Chromosome-Positive and/ or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Cord Blood Transplantation for the Treatment of Children and Young Adults with High Risk or Very High Risk Hematologic Malignancies
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Allogeneic Hematopoietic Stem Cell Transplantation Using Treosulfan Conditioning with Post-Transplant Cyclophosphamide for the Treatment of Hematologic Malignancies
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Standard-of-Care Reduced-Intensity Conditioning with Total Body Irradiation for the Treatment of Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
T Cell Receptor Alpha/Beta Depletion Peripheral Blood Stem Cell Transplantation for the Prevention of Graft Versus Host Disease in Children and Adults with Hematological Malignancies
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Specialized Stem Cell Transplant Product (Hematopoietic Progenitor Blood Cell Graft Cells) for the Treatment of Children, Adolescent and Young Adult Patients with Hematologic Cancers
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington